AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
 ABSTRACTS: CT016, CT018Â
Researchers from Â鶹ӳ» MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023. The studies, which describe results from a novel FGFR inhibitor and from new PARP/ATR inhibitor combinations, were featured in a plenary session highlighting novel biomarker-driven molecularly...
AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
ABSTRACT: CT006
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced...